玻璃体内地塞米松植入剂治疗视网膜色素变性黄斑囊样水肿的随机配对眼试验
这项随机、非对照、配对眼、单交叉临床试验纳入14例双眼黄斑囊样水肿(CME)且中心黄斑厚度>250 µm的视网膜色素变性(RP)患者,一眼接受玻璃体内地塞米松(DEX)植入剂、对侧眼观察,双眼均开始局部多佐胺治疗;第6个月时双眼CME>250 µm均可接受DEX植入,随访至第12个月。结果显示研究眼第2个月中心黄斑厚度显著下降(中位数-147.5 µm,P=0.001)且最佳矫正视力改善(中位数+6个字母,P=0.001),但第6个月无此效果;第6个月玻璃体内DEX植入在11只对侧眼和12只研究眼中产生与基线治疗相当的疗效;局部多佐胺未显示显著疗效。12个月内研究眼眼压>21 mmHg和 cataract 进展分别见于14.3%和40.0%。结论认为玻璃体内DEX植入既可降低黄斑厚度又可改善RP-CME视力,但需要重复注射。
要点
- 研究眼第2个月中心黄斑厚度中位数下降147.5 µm(P=0.001),最佳矫正视力中位数提高6个字母(P=0.001)。
- 第6个月时研究眼上述两项指标未见显著改善。
- 第6个月DEX植入在11只对侧眼和12只研究眼中疗效与基线治疗相当。
核心结论
- 玻璃体内DEX植入可降低RP-CME患者黄斑厚度并改善视力,但需要重复注射。
研究设计与样本
- 随机、非对照、配对眼、单交叉临床试验,纳入14例双眼CME且中心黄斑厚度>250 µm的RP患者,一眼随机接受玻璃体内DEX植入、对侧眼观察,双眼均开始局部多佐胺治疗,第6个月双眼CME>250 µm时均可接受DEX植入,随访至第12个月。
- 主要结局指标为第2个月中心黄斑厚度和最佳矫正视力相对基线的变化。
主要发现
- 研究眼第2个月中心黄斑厚度中位数下降147.5 µm(P=0.001),最佳矫正视力中位数提高6个字母(P=0.001)。
- 研究眼第6个月中心黄斑厚度和最佳矫正视力未见显著变化。
- 第6个月玻璃体内DEX植入在11只对侧眼和12只研究眼中产生与基线治疗相当的疗效。
- 局部多佐胺未显示显著治疗 efficacy。
- 12个月内研究眼眼压>21 mmHg占14.3%,cataract 进展占40.0%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the efficacy and safety of intravitreal dexamethasone (DEX) implant in retinitis pigmentosa patients with cystoid macular edema (CME). METHODS: In this randomized, noncontrolled, paired-eye, single crossover clinical trial, one eye of retinitis pigmentosa patients with bilateral CME with central macular thickness of >250 µm was randomized to intravitreal DEX implant while the fellow eye was observed. Both eyes were started on topical dorzolamide. At Month 6, DEX implant was eligible for both eyes when CME was >250 µm. Patients were followed up until Month 12. Primary outcome measures were the central macular thickness and best-corrected visual acuity changes from baseline at Month 2. RESULTS: Fourteen patients with bilateral RP-CME were included. Study eyes showed significant central macular thickness decrease (median, -147.5 µm; P = 0.001) and best-corrected visual acuity improvement (median, +6 letters; P = 0.001) at Month 2, but not at Month 6. Intravitreal DEX implant at Month 6 produced comparable efficacy to baseline treatment in 11 fellow eyes and 12 study eyes. Topical dorzolamide did not show significant therapeutic efficacy. During 12 months, elevated intraocular pressure of >21 mmHg and cataract progression were observed in 14.3% and 40.0% of study eyes. CONCLUSION: Intravitreal DEX implant can both reduce macular thickness and improve vision in RP-CME, while repeated injection is required.
引用
- Park UC, Park JH, Ma DJ, et al. A RANDOMIZED PAIRED-EYE TRIAL OF INTRAVITREAL DEXAMETHASONE IMPLANT FOR CYSTOID MACULAR EDEMA IN RETINITIS PIGMENTOSA. Retina. 2020. PMID: 31166248. doi:10.1097/IAE.0000000000002589
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。